Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

345.73
+3.441.00%
Post-market: 351.005.27+1.52%19:59 EDT
Volume:355.25K
Turnover:122.48M
Market Cap:7.71B
PE:-26.98
High:348.34
Open:340.98
Low:339.31
Close:342.29
52wk High:377.46
52wk Low:200.63
Shares:22.29M
Float Shares:11.00M
Volume Ratio:0.68
T/O Rate:3.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8155
EPS(LYR):-21.9007
ROE:-36.30%
ROA:-18.31%
PB:11.07
PE(LYR):-15.79

Loading ...

BRIEF-Madrigal Announces Two-Year Data From The Compensated Mash Cirrhosis Arm Of The Maestro-Nafld-1 Trial

Reuters
·
Feb 26

Madrigal Pharmaceuticals' Q4 Net Loss Narrows, Revenue Tops Estimates

MT Newswires Live
·
Feb 26

Madrigal: Q4 Earnings Snapshot

Associated Press Finance
·
Feb 26

Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q4 Net Revenue $103.3M, vs. FactSet Est of $99.1M

MT Newswires Live
·
Feb 26

Madrigal Pharmaceuticals Q4 2024 GAAP EPS $(2.71) Beats $(4.16) Estimate, Sales $103.22M Beat $98.56M Estimate. Cash And Equivalents Of $931.3M

Benzinga
·
Feb 26

BRIEF-Madrigal Pharmaceuticals Q4 EPS USD -2.71

Reuters
·
Feb 26

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire
·
Feb 26

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

GlobeNewswire
·
Feb 26

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), Madrigal Pharmaceuticals (MDGL)

TIPRANKS
·
Feb 25

John Paulson's Strategic Moves: Thryv Holdings Inc. Takes Center Stage with a 2.04% Portfolio Impact

GuruFocus.com
·
Feb 15

U.S. RESEARCH ROUNDUP-Airbnb, CVS Health, Roku

Reuters
·
Feb 14

Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISI

TIPRANKS
·
Feb 13

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

GlobeNewswire
·
Feb 12